Morita, Shinya

写真a

Affiliation

School of Medicine, Department of Urology (Shinanomachi)

Position

Assistant Professor/Senior Assistant Professor

Other Affiliation 【 Display / hide

  • School of Medicine

Career 【 Display / hide

  • 2009.04
    -
    2011.03

    Ogikubo Hospital

Academic Background 【 Display / hide

  •  

    Keio University

Licenses and Qualifications 【 Display / hide

  • Medical License

 

Research Areas 【 Display / hide

  • Life Science / Urology

Research Keywords 【 Display / hide

  • Renal Transplantation

 

Papers 【 Display / hide

  • A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report

    Iwasawa T., Kosaka T., Morita S., Mikami S., Nakamura K., Hongo H., Nishihara H., Oya M.

    BMC Medical Genomics (BMC Medical Genomics)  15 ( 1 )  2022.12

     View Summary

    Background: Abnormalities in homologous recombination contribute to the aggressive nature of castration-resistant prostate cancer. Retinoblastoma transcriptional corepressor 1 (RB1) and breast cancer 2 (BRCA2) exist close to each other in the same chromosome, and the significance of their concurrent loss has become a hot topic in the field of cancer research. Case presentation: A 61-year-old man presented with a chief complaint of a mass on his head and was diagnosed as multiple bone metastases from prostate cancer. He was treated with standard medication, but he died 2 years 6 months after being diagnosed with prostate cancer. Simultaneous biallelic loss of RB1 and BRCA2 as well as a truncating mutation of tumor protein p53 (TP53) were revealed by genomic analysis. Conclusion: To our knowledge, this is the first report of castration-resistant prostate cancer (CRPC) with BRCA2 and RB1 co-loss and TP53 mutation. To establish a treatment strategy for highly malignant cases with such multiple genetic features is important.

  • Endoscopic vaporization of benign prostatic hyperplasia using a contact 980 nm diode laser under antithrombotic therapy: A prospective survey

    Sanjo T., Tanaka N., Shinojima T., Yasumizu Y., Takeda T., Matsumoto K., Morita S., Kosaka T., Mizuno R., Asanuma H., Oya M.

    Asian journal of endoscopic surgery (Asian journal of endoscopic surgery)  15 ( 3 ) 585 - 590 2022.07

     View Summary

    INTRODUCTION: To prospectively clarify whether endoscopic contact laser vaporization of the prostate (CVP) can be safely performed even in patients undergoing antithrombotic therapy. METHODS: Fifty-five patients treated with CVP were enrolled. Patients were assigned to: (i) the antithrombotic therapy group (n = 21, 38%); or (ii) control group without antithrombotic therapy (n = 34, 62%). All patients in the antithrombotic therapy group continued all antithrombotic agents during the perioperative period and thereafter. RESULTS: No difference was noted in patient background between the two groups. In primary endpoints, decreases in the postoperative hemoglobin level were remarkable in the antithrombotic therapy group, while no serious effects were noted in either group. The control and antithrombotic therapy groups did not show a significant difference in the occurrence of catheter obstruction due to blood clots or serious hematuria following catheter removal. During follow-up, transurethral coagulation for hemostasis was needed only in the antithrombotic therapy group, with a frequency of transurethral coagulation of up to 14%. In secondary endpoints, no difference in the occurrence of perioperative or late-onset complications after surgery was noted between the two groups. Finally, no difference was noted in improvements in the International Prostate Symptom Score (IPSS), IPSS quality of life score, overactive bladder symptom score, maximum flow rate, or post-voiding residual urine volume between the two groups throughout the follow-up period. CONCLUSIONS: CVP can be performed safely and effectively in patients undergoing continuous antithrombotic therapy. However, the possibility of secondary bleeding after discharge in a subset of patients, such as those undergoing antithrombotic therapy, may be noted.

  • A low subcutaneous fat mass is a risk factor for the development of inguinal hernia after radical prostatectomy

    Umeda K., Takeda T., Hakozaki K., Yasumizu Y., Tanaka N., Matsumoto K., Morita S., Kosaka T., Mizuno R., Asanuma H., Oya M.

    Langenbeck's Archives of Surgery (Langenbeck's Archives of Surgery)  407 ( 7 ) 3107 - 3112 2022

    ISSN  14352443

     View Summary

    Purpose: Inguinal hernia (IH) after radical prostatectomy (RP) is a complication that impairs quality of life; however, the factors contributing to IH after RP remain unclear. Therefore, we herein attempted to identify the factors responsible for the development of IH after RP. Methods: We reviewed 622 patients who underwent laparoscopic or robot-assisted laparoscopic RP at our hospital between December 2011 and April 2020. The total fat area and visceral fat area were calculated at the level of the umbilicus using computed tomography, and the subcutaneous fat area (SFA) was calculated by subtracting the visceral fat area from the total fat area. The psoas muscle area was measured at the third lumbar vertebrae level using computed tomography to calculate the psoas muscle mass index, which is used in sarcopenia as an index of muscle mass. We investigated the risk factors for IH after laparoscopic or robot-assisted laparoscopic RP. Results: IH developed in 88 patients (16.7%). Fifty-seven of these patients underwent hernia repair at our hospital, and 56 (98.2%) had indirect hernias. A multivariate analysis identified SFA (odds ratios: 0.383, p < 0.001) as an independent predictor for the development of IH. Two-year IH-free survival rates were 77.3% in the small SFA group (SFA < 123 cm2) and 88.7% in the large SFA group (SFA ≥ 123 cm2) (p < 0.001). Conclusion: Subcutaneous fat was associated with the development of IH, particularly indirect IH, after laparoscopic or robot-assisted laparoscopic RP. An indirect IH prevention technique needs to be considered, particularly for patients with less subcutaneous fat.

  • Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy

    Mizuno R., Takamatsu K., Yasumizu Y., Tanaka N., Takeda T., Morita S., Matsumoto K., Kosaka T., Asanuma H., Mikami S., Oya M.

    Urologia Internationalis (Urologia Internationalis)  106 ( 11 ) 1145 - 1149 2022

    ISSN  00421138

     View Summary

    Introduction: The aim of this retrospective study was to elucidate predictors of survival in metastatic renal cell carcinoma (mRCC) patients in an International Metastatic Renal Cell Carcinoma Database Consortium favorable risk group treated with frontline therapy without immune checkpoint inhibitors. Methods: A total of 238 patients with mRCC were reviewed. Among them, 55 patients in favorable risk group treated with single-agent systemic therapy were retrospectively analyzed. Clinical and pathological data were retrieved and analyzed retrospectively. The prognostic effect of each marker on overall survival (OS) was investigated with univariate and multivariate Cox's proportional hazards regression models. Results: After a median follow-up of 46.2 months after first-line treatment initiation, the median progression-free survival (PFS) was 29.3 months, and the median OS has not been reached. The estimated percentage of patients who were alive at 12 and 24 months were 96.1 and 94.1%, respectively. Multivariate analysis revealed that the long-term duration of first-line treatment (hazard ratio [HR]: 0.972, 95% confidence interval [CI]: 0.944-0.997, p = 0.0299) and the metastases limited to lung (HR: 3.852, 95% CI: 1.080-24.502, p = 0.0361) were independent predictors for longer OS in favorable risk mRCC patients. Conclusion: First-line systemic therapy for favorable risk mRCC patients with a single agent resulted in relatively longer PFS and OS. A longer duration of first-line treatment and lung only metastases are correlated with longer OS.

  • Predictors of renal function after adrenalectomy in patients with Cushing or subclinical Cushing syndrome

    Kufukihara R., Takeda T., Hakozaki K., Yasumizu Y., Tanaka N., Matsumoto K., Morita S., Kosaka T., Mizuno R., Asanuma H., Miyashita K., Kurihara I., Oya M.

    International Journal of Urology (International Journal of Urology)   2022

    ISSN  09198172

     View Summary

    Purpose: The postoperative course of renal function remains unclear in Cushing syndrome. We examined changes in renal function after adrenalectomy in patients with Cushing syndrome and attempted to identify predictors of renal impairment. Methods: The study population comprised 76 patients who underwent adrenalectomy for Cushing and subclinical Cushing syndrome between 2001 and 2018. Renal function and other factors were evaluated pre-operation, at 1 postoperative month, and 1 postoperative year. We defined a ≥10% decrease in the estimated glomerular filtration rate at 1 postoperative year as renal impairment, and predictors associated with this reduction were investigated. The relationship between renal function and steroid replacement after surgery was also examined. Results: Mean pre-operative estimated glomerular filtration rate was 82.2 ml/min/1.73 m2. While mean estimated glomerular filtration rate was significantly lower at 1 postoperative month than the pre-operative value (71.7 ml/min/1.73 m2 [89.1%], p < 0.001), no significant differences were observed between 1 postoperative year and pre-operation (79.5 ml/min/1.73 m2 [97.6%], p = 0.108). Twenty-six patients (34.2%) developed renal impairment. A multivariate analysis identified a low pre-operative adrenocorticotropic hormone level as an independent predictor of renal impairment (odds ratio 6.30, p = 0.031). Among 43 patients with available records of steroid replacement history, 18 (41.9%) developed renal impairment. The ratio of patients with a reduced steroid replacement dose at 1 postoperative month was significantly lower among patients with renal impairment than those without (22.2% vs. 56.0%, p = 0.027). Conclusions: The pre-operative adrenocorticotropic hormone level was a predictor of renal function after adrenalectomy in patients with Cushing or subclinical Cushing syndrome.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Reviews, Commentaries, etc. 【 Display / hide

  • 挙児希望を主訴とした成人発症特発性低ゴナドトロピン男性子性腺機能低下症の2例

    大橋 正和, 松島 将史, 野中 昭一, 片岡 典子, 宇都 博文, 杉山 武, 吉田 宏之, 佐藤 卓, 森田 伸也, 高松 公晴

    日本生殖医学会雑誌 ((一社)日本生殖医学会)  67 ( 4 ) 347 - 347 2022.10

    ISSN  1881-0098

  • 接触式レーザー前立腺蒸散術の治療成績 後出血を来した症例の検討

    田中 伸之, 三條 丹星, 安水 洋太, 武田 利和, 松本 一宏, 森田 伸也, 小坂 威雄, 水野 隆一, 浅沼 宏, 大家 基嗣

    日本排尿機能学会誌 ((一社)日本排尿機能学会)  33 ( 1 ) 299 - 299 2022.09

    ISSN  1347-6513

  • バイオインフォマティクスを用いたカバジタキセル耐性前立腺癌リプログラミング薬剤のスクリーニング

    本郷 周, 小坂 威雄, 安水 洋太, 田中 伸之, 武田 利和, 森田 伸也, 松本 一宏, 水野 隆一, 大家 基嗣

    泌尿器外科 (医学図書出版(株))  35 ( 8 ) 866 - 866 2022.08

    ISSN  0914-6180

  • Sarcomatoid variantを含む腎盂癌に対するペンブロリズマブの治療経験

    村田 康彰, 田中 伸之, 岩佐 俊, 安水 洋太, 武田 利和, 松本 一宏, 森田 伸也, 小坂 威雄, 秋田 大宇, 三上 修治, 水野 隆一, 浅沼 宏, 陣崎 雅弘, 大家 基嗣

    泌尿器外科 (医学図書出版(株))  35 ( 7 ) 635 - 636 2022.07

    ISSN  0914-6180

  • 膀胱メラノーシスの1例

    渡邊 雅斗, 田中 伸之, 岩澤 智裕, 安水 洋太, 武田 利和, 森田 伸也, 松本 一宏, 小坂 威雄, 秋田 大宇, 上野 彰久, 新井 恵吏, 水野 隆一, 浅沼 宏, 陣崎 雅弘, 大家 基嗣

    泌尿器外科 (医学図書出版(株))  35 ( 7 ) 640 - 640 2022.07

    ISSN  0914-6180

display all >>

Presentations 【 Display / hide

  • 診断が困難であった前立腺肉腫の1例

    ISHIDA MASARU

    日本泌尿器科学会東京地方会 (東京) , 

    2006.07

    Oral presentation (general)

  • ABO不適合生体腎移植後にCMVアンチゲネミア陽性をきたした2例

    KOUNO HIDAKA

    第39回臨床腎移植学会 (鬼怒川) , 

    2006.01

    Oral presentation (general)

  • 糖尿病性腎症による腎不全に対する高齢者腎移植の1例

    MORITA SHINYA

    第39回臨床腎移植学会 (鬼怒川) , 

    2006.01

    Oral presentation (general)

  • 後腹膜腔に発生し,膀胱の著明な圧迫を来した偽粘液腫の1例

    Morita Shinya, Kouno Hidaka, Shinojima Toshiaki, Oohigashi Takashi, Murai Masaru

    第555回日本泌尿器科学会東京地方会 (東京) , 

    2002.07

    Oral presentation (general)

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 移植腎長期生着へ向けた慢性移植腎症非免疫学的メカニズムの解明と予防法の開発

    2019.04
    -
    2022.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

 

Courses Taught 【 Display / hide

  • LECTURE SERIES, UROLOGY

    2023

  • LECTURE SERIES, UROLOGY

    2022

  • LECTURE SERIES, UROLOGY

    2021

  • LECTURE SERIES, UROLOGY

    2020

  • LECTURE SERIES, UROLOGY

    2019